Atopic dermatitis and inflammatory skin diseaseDirect infant UV light exposure is associated with eczema and immune development
Graphical abstract
Section snippets
Study design
This study was a double-blind, placebo-controlled RCT. Healthy term (delivered >37 weeks' gestation) singleton infants were recruited before 28 days of age. All the infants had a first-degree relative (mother, father, or sibling) with a history of allergic disease (asthma, eczema, and allergic rhinitis) to reduce heterogeneity in immune function outcomes. This study excluded infants whose mothers had smoked during pregnancy or had an underlying immunodeficiency/autoimmune disease or those with
Infant characteristics
Enrollment began on October 9, 2012, and ended on January 23, 2017. A total of 195 infants were randomized into the trial, 97 to the intervention vitamin D group and 98 to the placebo group. Fig 1 shows the participant flow diagram. Baseline characteristics of the 2 groups are described in Table I. Allocations in the vitamin D group compared with those in the placebo group were not different across seasons (P = .24). Data collection was completed on July 4, 2017. Ninety-two percent (180/195) of
Discussion
This study is the first to demonstrate an association between greater direct infant UV light exposure in the first 3 months of life and both lower incidence of medically diagnosed infant eczema and lower levels of immune factors associated with allergic inflammation at 6 months of age. Greater UV light exposure was associated with lower production of IL-2, which plays a central role in differentiation of naive CD4 T cells into TH2 cells, with potential implications for allergic disease
References (32)
- et al.
Regional differences in EpiPen prescriptions in the United States: the potential role of vitamin D
J Allergy Clin Immunol
(2007) - et al.
Prevalence of eczema and food allergy is associated with latitude in Australia
J Allergy Clin Immunol
(2012) - et al.
Climatic factors are associated with childhood eczema prevalence in the United States
J Invest Dermatol
(2013) - et al.
The link between serum vitamin D level, sensitization to food allergens, and the severity of atopic dermatitis in infancy
J Pediatr
(2014) - et al.
Cord serum 25-hydroxyvitamin D and risk of early childhood transient wheezing and atopic dermatitis
J Allergy Clin Immunol
(2014) - et al.
Characterization and application of UV detector spore films: the sensitivity curve of a new detector system provides good similarity to the action spectrum for UV-induced erythema in human skin
J Photochem Photobiol B
(1997) - et al.
Guidelines of care for atopic dermatitis
J Am Acad Dermatol
(2004) - et al.
Potential role of reduced environmental UV exposure as a driver of the current epidemic of atopic dermatitis
J Allergy Clin Immunol
(2015) - et al.
Biopositive effects of low-dose UVB on epidermis: coordinate upregulation of antimicrobial peptides and permeability barrier reinforcement
J Invest Dermatol
(2008) - et al.
Food allergy: riding the second wave of the allergy epidemic
Pediatr Allergy Immunol
(2011)
Latitude, sunlight, vitamin D, and childhood food allergy/anaphylaxis
Curr Allergy Asthma Rep
Vitamin D insufficiency is associated with challenge-proven food allergy in infants
J Allergy Clin Immunol
Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells
J Immunol
Availability of 25-hydroxyvitamin D(3) to APCs controls the balance between regulatory and inflammatory T cell responses
J Immunol
Modulation of the immune system by UV radiation: more than just the effects of vitamin D?
Nat Rev Immunol
American Academy of Pediatrics Section on Breastfeeding, American Academy of Pediatrics Committee on Nutrition. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents
Pediatrics
Cited by (0)
D.J.P. is supported by a Career Development Fellowship funded from the Medical Research Future Fund Next Generation Clinical Researchers Program. This study was supported by grants from Telethon–New Children's Hospital Research Fund, Australia; Asthma Foundation of Western Australia, Australia; and the Princess Margaret Hospital Foundation, Australia. The trial intervention and placebo control products were donated by Ddrops, Woodbridge, Ontario, Canada.
Disclosure of potential conflict of interest: S. L. Prescott reports nonfinancial support from Danone and from Bayer and personal fees from Swisse and from Sanofi, all outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.
- ∗
These authors contributed equally to this work.